Position in LPCN
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$47,784
-$388,684 QoQ
Shares Held
18,666
-28.0% QoQ
Ownership
0.226%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#19
of 36 holders
Holding Since
Jun 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LPCN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. LPCN ranks #155 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
187,337 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in LPCN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $47,784 | 18,666 | Shares | Sole | 2026-08-06 | |
| 2021-12-31 | $436,468 | 440,432 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $343,685 | 315,308 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $198,129 | 141,521 | Shares | Sole | 2021-08-05 | |
| 2021-03-31 | $190,249 | 125,993 | Shares | Sole | 2021-05-10 | |
| 2020-12-31 | $252,949 | 185,992 | Shares | Sole | 2021-02-03 | |
| 2020-09-30 | $112,541 | 79,817 | Shares | Sole | 2020-11-06 | |
| 2020-06-30 | $76,063 | 60,368 | Shares | Sole | 2020-08-11 | |
| No filing history on record for this holder in this stock. | ||||||